In vitro activity of ceftazidime-avibactam against isolates in a phase 3 open-label clinical trial for complicated intra-abdominal and urinary tract infections caused by ceftazidime-nonsusceptible gram-negative pathogens

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 2, 2017, Pages

  Stone, Gregory G ^a   Bradford, Patricia A ^a   Newell, Paul ^a   Wardman, Angela ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Ceftazidime nonsusceptible; Ceftazidime avibactam; In vitro activity

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; CEFTAZIDIME;

ABDOMINAL INFECTION; ARTICLE; BACTERIUM ISOLATE; DRUG DISTRIBUTION; DRUG SCREENING; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MIC50; MIC90; NONHUMAN; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; URINARY TRACT INFECTION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; INTRAABDOMINAL INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CEFTAZIDIME; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS;

EID: 85010928633     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01820-16     Document Type: Article

References (14)

1. Stachyra T, Levasseur P, Pechereau MC, Girard AM, Claudon M, Miossec C, Black MT. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 64:326-329. https://doi.org/10.1093/jac/dkp197.
2. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663-11668. https://doi.org/10.1073/pnas.1205073109.
3. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, III, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73:159-177. https://doi.org/10.1007/s40265-013-0013-7.
4. Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K. 2015. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 59:1789-1793. https://doi.org/10.1128/AAC.04191-14.
5. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. 2016. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16:661-673. https://doi.org/10.1016/S1473-3099(16)30004-4.
6. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2009. Methods of dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
8. US Food and Drug Administration. 2005. Tygacil prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021821s026s031lbl.pdf.
9. Mendes RE, Castanheira M, Woolsey LN, Costello SE, Stone GG, Flamm RK, Jones RN. 2015. β-Lactamase characterization of baseline Enterobacteriaceae from a phase 3 trial of ceftazidime-avibactam for the treatment of infections caused by ceftazidime-non-susceptible pathogens, abstr 1176. ID Week, San Diego, CA, 7 to 11 October 2015.
10. Stone G, Reiszner E, Hackel M, Badal R. 2016. Activity of ceftazidime-avibactam (CAZ-AVI) against ESBL positive Enterobacteriaceae (Entb) and CAZ-resistant Pseudomonas aeruginosa from urinary tract infections in Asia/South Pacific, Europe, Middle East/Africa and Latin America in the 2013 INFORM surveillance program, abstr MONDAY-268. ASM Microbe, Boston, MA, 16 to 20 June 2016.
11. Levasseur P, Girard AM, Claudon M, Goossens H, Black MT, Coleman K, Miossec C. 2012. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 56:1606-1608. https://doi.org/10.1128/AAC.06064-11.
12. Hackel M, Stone G, DeJonge B, Sahm DF. 2016. In vitro activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa from Europe 2012-2014, abstr P0297. 26th European Congress on Clinical Microbiology and Infectious Diseases, Amsterdam, the Netherlands, 9 to 12 April 2016.
13. Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN. 2015. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother 59:3656-3659. https://doi.org/10.1128/AAC.05024-14.
14. Flamm RK, Stone GG, Sader HS, Jones RN, Nichols WW. 2014. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother 26:333-338. https://doi.org/10.1179/1973947813Y.0000000145.